Sutro Biopharma (STRO) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $11.46, +8.94% vs the prior close of $10.52.
- Volume 418.40K shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
STRO jumps 8.9% to $11.46. Closed at $11.46, +8.94% vs the prior close of $10.52. Day range $10.51–$11.65, opened at $10.54.
STRO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — STRO jumps 8.9% to $11.46
- Closed at $11.46, +8.94% vs the prior close of $10.52. Day range $10.51–$11.65, opened at $10.54.
- Volume was 418.40K shares, 1.4x its 50-day average of 305.51K.
- Price is -37.1% vs its 50-day average ($18.21) and -50.4% vs its 200-day average ($23.11).
- 52-week range $7.15–$43.85; today's close sits at 12% of that range, 73.9% below the 52-week high.
Oct 14, 2026 — STRO slides 4.5% to $10.52, a 6-month low, 4 down days in a row
- Closed at $10.52, -4.45% vs the prior close of $11.01. Day range $10.36–$11.31, opened at $10.99.
- Volume was 489.80K shares, 1.6x its 50-day average of 298.67K.
- Price is -43.1% vs its 50-day average ($18.48) and -54.5% vs its 200-day average ($23.11).
- 52-week range $7.15–$43.85; today's close sits at 9% of that range, 76.0% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — STRO slides 17.1% to $11.01, a 6-month low, 3 down days in a row
- Closed at $11.01, -17.09% vs the prior close of $13.28. Day range $10.84–$13.19, opened at $13.11.
- Volume was 406.70K shares, 1.4x its 50-day average of 294.13K.
- Price is -41.4% vs its 50-day average ($18.79) and -52.4% vs its 200-day average ($23.12).
- 52-week range $7.15–$43.85; today's close sits at 11% of that range, 74.9% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — STRO slides 6.9% to $13.28, a 6-month low
- Closed at $13.28, -6.94% vs the prior close of $14.27. Day range $12.83–$14.21, opened at $14.08.
- Volume was 298.70K shares, 1.0x its 50-day average of 291.42K.
- Price is -30.4% vs its 50-day average ($19.07) and -42.6% vs its 200-day average ($23.12).
- 52-week range $7.15–$43.85; today's close sits at 17% of that range, 69.7% below the 52-week high.
Oct 9, 2026 — STRO slides 6.9% to $14.27, a 6-month low
- Closed at $14.27, -6.85% vs the prior close of $15.32. Day range $14.05–$15.42, opened at $15.31.
- Volume was 256.20K shares, 0.9x its 50-day average of 289.27K.
- Price is -26.0% vs its 50-day average ($19.29) and -38.2% vs its 200-day average ($23.10).
- 52-week range $7.15–$43.85; today's close sits at 19% of that range, 67.5% below the 52-week high.
Oct 8, 2026 — STRO jumps 4.5% to $15.32
- Closed at $15.32, +4.50% vs the prior close of $14.66. Day range $14.40–$16.21, opened at $14.46.
- Volume was 500.00K shares, 1.8x its 50-day average of 283.01K.
- Price is -21.4% vs its 50-day average ($19.50) and -33.6% vs its 200-day average ($23.08).
- 52-week range $7.15–$43.85; today's close sits at 22% of that range, 65.1% below the 52-week high.
Oct 7, 2026 — STRO rises 1.5% to $14.66
- Closed at $14.66, +1.45% vs the prior close of $14.45. Day range $14.01–$15.78, opened at $14.24.
- Volume was 232.50K shares, 0.8x its 50-day average of 283.28K.
- Price is -25.4% vs its 50-day average ($19.66) and -36.4% vs its 200-day average ($23.06).
- 52-week range $7.15–$43.85; today's close sits at 20% of that range, 66.6% below the 52-week high.
Oct 6, 2026 — STRO slides 4.5% to $14.45, a 6-month low, 4 down days in a row
- Closed at $14.45, -4.49% vs the prior close of $15.13. Day range $14.37–$15.47, opened at $15.14.
- Volume was 162.80K shares, 0.6x its 50-day average of 284.43K — lighter than usual.
- Price is -27.2% vs its 50-day average ($19.84) and -37.2% vs its 200-day average ($23.03).
- 52-week range $7.15–$43.85; today's close sits at 20% of that range, 67.0% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — STRO dips 1.4% to $15.13, a 6-month low, 3 down days in a row
- Closed at $15.13, -1.43% vs the prior close of $15.35. Day range $14.27–$15.46, opened at $15.46.
- Volume was 160.40K shares, 0.6x its 50-day average of 287.79K — lighter than usual.
- Price is -24.5% vs its 50-day average ($20.03) and -34.2% vs its 200-day average ($23.00).
- 52-week range $7.15–$43.85; today's close sits at 22% of that range, 65.5% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — STRO slides 3.9% to $15.35
- Closed at $15.35, -3.88% vs the prior close of $15.97. Day range $14.59–$16.15, opened at $16.15.
- Volume was 372.10K shares, 1.3x its 50-day average of 285.56K.
- Price is -23.9% vs its 50-day average ($20.18) and -33.2% vs its 200-day average ($22.97).
- 52-week range $7.15–$43.85; today's close sits at 22% of that range, 65.0% below the 52-week high.
STRO latest news & SEC filings
Every SEC filing by or about STRO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gerber Hans-Peter converted options/RSUs into 3,750 shares on Sep 18, 2026; now holds 13,712
- Gerber Hans-Peter had withheld for taxes 1,345 shares at $15.34 (≈$20.63K) on Sep 18, 2026; now holds 12,367
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $9.84M (prior year $63.74M) (-84.6% vs Jun 30, 2025)
- Net income: -$38.53M (prior year -$11.50M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$2.33 (prior year -$1.35) (loss widened vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade STRO
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 23, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.74% (largest 17.1%). That is a volatile stock.
- Liquidity: about 302.68K shares (≈$3.47M) trade per day on average.
- 52-week position: $11.46 vs a range of $7.15–$43.85 (12% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Dec 3, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 5 open-market buys, 0 sales; latest: Jane Chung bought 12,500 shares on Oct 15, 2025.
- Latest filings: 10-Q Aug 12, 2026; 8-K Aug 12, 2026; 8-K Jun 8, 2026.
- Share count: 16.58M shares outstanding (Aug 7, 2026), -80.4% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
STRO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 10.54 | 11.65 | 10.51 | 11.46 | 418.40K |
| Oct 14, 2026 | 10.99 | 11.31 | 10.36 | 10.52 | 489.80K |
| Oct 13, 2026 | 13.11 | 13.19 | 10.84 | 11.01 | 406.70K |
| Oct 12, 2026 | 14.08 | 14.21 | 12.83 | 13.28 | 298.70K |
| Oct 9, 2026 | 15.31 | 15.42 | 14.05 | 14.27 | 256.20K |
| Oct 8, 2026 | 14.46 | 16.21 | 14.40 | 15.32 | 500.00K |
| Oct 7, 2026 | 14.24 | 15.78 | 14.01 | 14.66 | 232.50K |
| Oct 6, 2026 | 15.14 | 15.47 | 14.37 | 14.45 | 162.80K |
| Oct 5, 2026 | 15.46 | 15.46 | 14.27 | 15.13 | 160.40K |
| Oct 2, 2026 | 16.15 | 16.15 | 14.59 | 15.35 | 372.10K |
| Oct 1, 2026 | 16.07 | 16.32 | 15.62 | 15.97 | 196.90K |
| Sep 30, 2026 | 16.22 | 16.66 | 15.85 | 16.11 | 134.00K |
| Sep 29, 2026 | 16.05 | 16.27 | 15.74 | 16.10 | 202.40K |
| Sep 28, 2026 | 15.89 | 16.24 | 15.20 | 16.03 | 165.70K |
| Sep 25, 2026 | 15.61 | 16.19 | 14.95 | 15.98 | 292.10K |
| Sep 24, 2026 | 15.68 | 16.00 | 15.15 | 15.71 | 252.90K |
| Sep 23, 2026 | 16.09 | 16.17 | 15.56 | 15.73 | 294.00K |
| Sep 22, 2026 | 16.43 | 16.55 | 16.00 | 16.13 | 246.20K |
| Sep 21, 2026 | 14.99 | 16.52 | 14.99 | 16.35 | 320.30K |
| Sep 18, 2026 | 15.58 | 15.58 | 14.81 | 15.34 | 651.40K |
About Sutro Biopharma
Sutro Biopharma (STRO) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SOUTH SAN FRANCISCO, CA. Fiscal year ends December 31. SEC CIK 1382101.
STRO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jane Chung | Chief Executive Officer | Mar 6, 2026 |
| Michael Dybbs | Director | Jun 9, 2026 |
| Heidi Hunter | Director | Jun 9, 2026 |
| Sukhi Jagpal | Director | Jun 9, 2026 |
| Joseph M Lobacki | Director | Jun 9, 2026 |
| Connie Matsui | Director | Jun 9, 2026 |
| James P Panek | Director | Jun 9, 2026 |
| Daniel H Petree | Director | Jun 9, 2026 |
| Jon Marc Wigginton | Director | Jun 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Gregory K. Chow | CFO | Jun 2, 2026 |
| Jane Chung | Chief Executive Officer | Mar 6, 2026 |
| Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | Sep 22, 2026 |
| David Pauling | Chief Admin. Ofcr. & GC | Mar 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Oct 15, 2025 | Jane Chung | Buy | 12,500 | $0.80 |
| Oct 15, 2025 | Hans-Peter Gerber | Buy | 17,000 | $0.80 |
| Oct 15, 2025 | David Pauling | Buy | 12,504 | $0.80 |
| Oct 15, 2025 | Gregory K. Chow | Buy | 19,750 | $0.81 |
| Oct 15, 2025 | Connie Matsui | Buy | 50,000 | $0.80 |
STRO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $102.48M | $-191.09M | -22.49 | $-177.23M |
| Dec 31, 2024 | $62.04M | $-227.46M | -29.40 | $-191.54M |
| Dec 31, 2023 | $153.73M | $-106.79M | -1.78 | $-111.62M |
| Dec 31, 2022 | $67.77M | $-119.20M | -2.35 | $3.55M |
| Dec 31, 2021 | $61.88M | $-105.54M | -2.29 | $-81.68M |
Latest balance sheet: total assets $194.46M, total liabilities $297.78M, cash $54.34M (as of Jun 30, 2026).
STRO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $21.30 |
| May 14, 2026 | 8-K Item 2.02 (results) | $38.42 |
| Mar 23, 2026 | 8-K Item 2.02 (results) | $21.33 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $9.40 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $8.00 |
| May 8, 2025 | 8-K Item 2.02 (results) | $9.60 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $12.50 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $39.60 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Mar 25, 2024 | 8-K Item 2.02 (results) | — |
| Jan 8, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on STRO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.